<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138709</url>
  </required_header>
  <id_info>
    <org_study_id>CC-0196-09-A721</org_study_id>
    <nct_id>NCT01138709</nct_id>
  </id_info>
  <brief_title>Vitala 12 Hour Wear Test With Convex Products</brief_title>
  <official_title>Phase II Vitala 12 Hour Wear Test With Convex Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConvaTec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ConvaTec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this phase II clinical trial is to assess the safety of the Vitala™
      device during 12 hours of daily wear with convex products.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>29 Days</time_frame>
    <description>Assess safety during 12 hours of Vitala™ device wear with convex products by measuring the frequency of adverse events relating to the stoma (including gastrointestinal, stomal and surrounding skin events), and stomal vascularity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy:</measure>
    <time_frame>29 Days</time_frame>
    <description>Restoration of Continence (absence of fecal leakage around the device) for 29 days of Vitala™ daily wear according to the following parameters:
Proportion of subjects with leakage over time.
Overall weighted leakage rate.
Proportion of subjects without leakage.
Self-rating of ability to restore continence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>29 Days</time_frame>
    <description>Vitala™ device will also be evaluated for the following efficacy parameters:
Security of the device.
Flange to flange security.
Device wear time.
Subject comfort.
Control of odor.
Control of noise due to flatus release from the stoma.
Ease of use of the device during application and removal.
Subject acceptance of the device.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>End Colostomy</condition>
  <arm_group>
    <arm_group_label>Convexity/Vitala</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all enrolled Subjects, STAGE 1 (Days 1 - 14 equals Convex Product Wear Period followed by, for those who successfully complete Stage I, weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 15 to 21), followed by 8 hours of daily wear time per week (Day 22 to 28), followed by 12 hours of daily wear time (Days 29 to 43).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitala</intervention_name>
    <description>Vitala™ Continence Control Device</description>
    <arm_group_label>Convexity/Vitala</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is of legal consenting age.

          -  Is able to read, write, and understand the study, the required procedures, and the
             study related documentation.

          -  Has signed the informed consent.

          -  Has an end colostomy of at least 12 weeks duration with formed or semi-formed
             effluent.

          -  Currently uses a convex skin barrier wafer or uses convex inserts into standard skin
             barrier wafers or is willing to wear SUR-FIT Natura® Durahesive® Skin Barrier with
             CONVEX-IT® or SUR-FIT Natura® Disposable Convex Inserts in 45mm or 57mm flange sizes.
             Enrollment will target 15 current convex product users and 10 non convex users.

          -  The investigator is relatively sure the subject will be able to wear a SUR-FIT Natura®
             Durahesive® Skin Barrier with CONVEX-IT® in 45mm or 57mm flange size with a stoma
             opening size from 13mm up to 50mm or the SUR-FIT Natura® Disposable Convex Inserts in
             45mm or 57mm flange sizes.

          -  Is willing to remove and replace the skin barrier wafer after three days, more often
             if desired, during Stage 2.

          -  Has a stoma that protrudes no more than 2 cm at rest (lying down on back).

          -  Has demonstrated success in wearing a traditional pouching system. (Investigator
             judgment)

          -  Is willing to participate in the trial for a total of 43 days.

          -  Is willing to meet with the investigator for a total of 5 scheduled visits plus
             additional visits as deemed necessary by the investigator.

          -  Has the ability to do complete self-care.

        Exclusion Criteria:

          -  Has known skin sensitivity to any component of the products being tested.

          -  Has a skin rating of &quot;2&quot; or greater according to the Skin Rating Scale.

          -  Has peristomal ulcerations, peristomal pressure necrosis, parastomal hernia, Caput
             Medusa or mucocutaneous separation.

          -  Is receiving radiation in the area of the pouching system.

          -  Is receiving chemotherapy other than a stable regimen of maintenance chemotherapy.

          -  Requires a pouch belt while wearing Vitala™.

          -  Requires a moldable skin barrier.

          -  Has participated in a clinical study within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dheerendra Kommala, MD</last_name>
    <role>Study Director</role>
    <affiliation>ConvaTec Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Non-Institutional Investigator</name>
      <address>
        <city>Tucson,</city>
        <state>Arizona</state>
        <zip>85742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ET Nursing Services</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Restored Images</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Image Specialties</name>
      <address>
        <city>St. Joseph,</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-Institutional Investigator</name>
      <address>
        <city>Reynoldsburg</city>
        <state>Ohio</state>
        <zip>43068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

